Your AI-Trained Oncology Knowledge Connection!
Hayley Virgil is a senior editor with CancerNetwork. When she isn't traveling to conferences and championing health equity in the oncology space, she can be found hiking, foraging wild plants, gardening, sewing ballgowns, practicing embroidery, or playing video games.
Based on data showing that patients with metastatic castration-resistant prostate cancer may achieve benefit following treatment with olaparib plus abiraterone and prednisone or prednisolone regardless of homologous recombination repair mutational status, the FDA gave the combination priority review.
Experts indicated that 77% of women with lung cancer who were surveyed reported having moderate to severe sexual dysfunction.
After approximately 3.5 years of follow-up, patients with treatment-naive extensive-stage small cell lung cancer continued to derive survival benefit from pembrolizumab and etoposide.
Patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations experienced a survival benefit following treatment with tremelimumab plus durvalumab and chemotherapy in the first line.
Data from the phase 2 NADIM II trial appear to reinforce the superiority of nivolumab and chemotherapy vs chemotherapy alone after the regimen significantly improved overall survival progression-free survival, and pathologic complete response in patients with stage IIIA/B non–small cell lung cancer, according to investigators.
Data indicate that atezolizumab may achieve overall survival benefit compared with best supportive care in resected non–small cell lung cancer.
Four subgroups of patients with MET exon 14 skipping non–small cell lung cancer demonstrated unique signaling pathways and significant differentially-expressed genes.
Patients with stage III unresectable non–small cell lung cancer experienced a sustained progression-free survival benefit following treatment with consolidation sugemalimab.
Findings from the phase 2 NADIM trial reinforced the rationale for using neoadjuvant chemoimmunotherapy to treat patients with stage IIIA resectable non–small cell lung cancer based on differences between pathologic complete responders and non–pathologic complete responders
A challenging patient population with advanced non–small cell lung cancer and resistance to common immunotherapeutics appeared to derive promising benefit from treatment with eftilagimod alpha plus pembrolizumab.
Patients with metastatic hormone-sensitive prostate cancer can now receive treatment with oral darolutamide plus docetaxel following its approval by the FDA.
Nicholas Coupe, MBBS, PhD, discusses promising preliminary findings from a phase 1/2 study assessing the use of IMM60 in patients with advanced melanoma and non–small cell lung cancer.
Although patients with unresectable hepatocellular carcinoma initially appeared to have survival benefit following treatment with pembrolizumab and lenvatinib vs lenvatinib alone, the findings did not meet statistical significance.
Development on CYAD-101 as a treatment for patients with refractory/metastatic colorectal cancer continues after the FDA has lifted a clinical hold on the phase 1b CYAD-101-002 trial.
Treatment with adjuvant radiotherapy in the prone position lowered the odds of desquamation in patients with breast cancer and large breast size.
Patients with relapsed/refractory B-cell malignancies who received zandelisib at 60 mg via an intermittent dosing schedule experienced a low incidence of grade 3 or higher adverse effects.
Patients with Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder carcinoma in situ appear to benefit from treatment with N-803, leading to the FDA accepting its biologics license application.
Patients with relapsed/refractory follicular lymphoma with 2 or more prior therapies experienced promising safety and remission rates following treatment with mosunetuzumab.
Patients with metastatic unresectable leiomyosarcoma in the first line benefitted more from doxorubicin and trabectedin compared with doxorubicin alone.
Patients with borderline resectable pancreatic ductal adenocarcinoma experienced favorable overall survival following treatment with mFOLFIRINOX alone, with additional hypofractionated radiotherapy showing little benefit.
Distinct clinical, genomic, and immunologic features were observed among patients with KRAS G12D–positive non–small cell lung compared with those with other types of KRAS positivity.
Patients with relapsed/refractory multiple myeloma appear to benefit from treatment with teclistamab, which was given a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Patients in Europe who have multiple myeloma and have received at least 1 previous therapy can now receive treatment with selinexor plus bortezomib and low-dose dexamethasone following its full marketing authorization by the European Commission.
The needle might be further pushed forward for precision medicine through exploration of novel proteins such as CDC37 and MAOB in patients with metastatic colorectal cancer.
The phase 3 KEYNOTE-412 trial assessing pembrolizumab and consolidation chemoradiotherapy plus maintenance pembrolizumab in unresected locally advanced head and neck squamous cell carcinoma missed its primary end point of event-free survival improvement vs matched placebo.
Although European Leukemia Net 2017 Risk Stratification was ineffective for predicting outcomes following allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia, pre-transplant Wilms tumor gene 1 expression and FLT3-ITD mutation demonstrated promising predictive ability.
Post-marketing surveillance data further confirmed carfilzomib to be a well-tolerated and promising option among patients with relapsed/refractory multiple myeloma, although investigators emphasize the importance of watching for cardiac comorbidities.
European patients with unresectable or metastatic HER2-positive breast cancer are now able to receive treatment with trastuzumab deruxtecan following 1 or more previous anti-HER2 regimens.
Patients with ERBB2-positive esophagogastric adenocarcinoma appeared to experience improved efficacy following treatment with a combination of trastuzumab and nivolumab plus leucovorin, fluorouracil, and oxaliplatin vs historical data.
MAOB and CDC37 gene expression appear to be 2 new promising targets in advanced colorectal cancer, according to Heinz-Josef Lenz, MD.
